Alkermes Inc. plc (ALKS) Financials
Key financial figures for Alkermes Inc. plc (Q3 2026).
Q3 2026 revenue was $480.1M versus $394.2M a year earlier, with LUMRYZ (acquired with Avadel) adding $89.9M, while GAAP net income fell to $16.3M from $82.8M. Total revenues were $480.1M versus $394.2M in Q3 2025 (about +22%, calculated from the printed figures); proprietary net sales were $417.3M versus $317.4M. The release carries no analyst estimate, so this is a prior-year comparison only. LUMRYZ contributed $89.9M (nil in Q3 2025, before the Avadel acquisition closed Feb. 12, 2026), with about 4,100 patients on therapy at quarter end. On the outlook: The release reiterates 2026 financial expectations as set forth in the July 28, 2026 release and prints no new ranges; the July 28 release listed total revenues of $1,730-$1,840M, VIVITROL $460-$480M, LYBALVI $380-$400M, ARISTADA $365-$385M, LUMRYZ $315-$335M (Feb. 12 to Dec. 31, 2026) and Adjusted EBITDA of $370-$410M. Figures are for Q3 2026, as Alkermes plc reported them.
- Revenue
- $480M
- Net Income
- $16M
- EPS
- $0.10
- Total Assets
- $4.4B
- Operating Cash Flow
- $93M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $480M | $16M | $0.09 | 7.5% | $90M |
| Q2 FY2026 | $496M | $501K | $0.00 | 3.71% | $137M |
| Q1 FY2026 | $393M | -$66M | -$0.40 | -12.29% | -$170M |
| Q4 FY2025 | $385M | $49M | $0.29 | 15.11% | |
| Q3 FY2025 | $394M | $83M | $0.49 | 22.6% | $84M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $1.5B | $242M | $1.43 | 17.21% | $480M |
| FY2024 | $1.6B | $367M | $2.17 | 27% | $406M |
| FY2023 | $1.7B | $356M | $2.10 | 24.9% | $353M |
Frequently asked questions
What was Alkermes plc's revenue last quarter?
Alkermes plc reported revenue of $480.1 million for Q3 FY2026, up 21.8% from the same period a year earlier.
Is Alkermes plc profitable?
Yes. Alkermes plc reported net income of $16.3 million for Q3 FY2026, a net margin of 3.39% on revenue.
How has Alkermes plc's margin trended?
Operating margin was 7.5% in Q3 FY2026, compared with 22.6% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Alkermes plc generate?
Alkermes plc generated free cash flow of $90.1 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Alkermes Inc. plc on SentiSense, with up to forty quarters and twenty fiscal years of history.